Hi Steve, agree with a couple of your points mate.
Personally I am not very happy at where we are at this time, only ray of positivity is the expansion of OBJ tech in P&G products ..... how meaningful though will this be?
In regards to forecasts by OBJ; OBJ does sell something, it sells its IP.
Understand that it is tied up with the P&G end product; why would the Market then gamble on a ‘pig in the poke’, because without any type of forecasts isn’t this what it becomes?
That P&G are not going to trumpet any internal forecasts; then when OBJ quarterly reports come and revenue figures are still ordinary what do we make of that?
Failure of P&G to sell enough of their own product in association with OBJ science?, not sure it works like that!
Really not sure why OBJ being unable to provide forecasts has anything to do with P&G ‘secrecy’ on their own internal forecasts!
- Forums
- ASX - By Stock
- WFL
- The Procter & Gamble Company (PG) Q3 2019 Earnings Call Transcript
The Procter & Gamble Company (PG) Q3 2019 Earnings Call Transcript, page-26
Featured News
Add WFL (ASX) to my watchlist
(20min delay)
|
|||||
Last
0.3¢ |
Change
0.000(0.00%) |
Mkt cap ! $1.478M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Featured News
WFL (ASX) Chart |
Day chart unavailable
The Watchlist
ACW
ACTINOGEN MEDICAL LIMITED
Will Souter, CFO
Will Souter
CFO
Previous Video
Next Video
SPONSORED BY The Market Online